Files

Download

Download Full Text (252 KB)

Description

AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than $15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by:

  • Using current literature to inform clinical care
  • Standardizing practice
  • Using data to track and guide implementation

Publication Date

2018

Keywords

Bivaliruidin, Heparin, Cost, Percutaneous intervention, Standardized practice

Disciplines

Cardiology | Other Nursing | Pharmacoeconomics and Pharmaceutical Economics

Comments

2018 Nurses Week Poster

Decreasing Unnecessary Pharmacy Cost in the Cath Lab

Share

COinS